J J Lynch

Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.

J J Baldwin, M. Sanguinetti, R. Freidinger, 1997, Journal of medicinal chemistry.

Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.

J. Vacca, S. Gardell, T. Tucker, 1997, Journal of medicinal chemistry.

Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.

S. Brady, J. Vacca, S. Gardell, 1998, Journal of medicinal chemistry.

Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.

Lawrence C Kuo, Daniel R McMasters, Youwei Yan, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.

M. Bock, R. Freidinger, J. Vacca, 1997, Journal of medicinal chemistry.

L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor.

J. Vacca, J. Shafer, Z. Chen, 1998, Bioorganic & medicinal chemistry letters.

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support.

S. Brady, J. Vacca, S. Gardell, 1998, Journal of medicinal chemistry.

Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.

A. D. Rodrigues, E S Walsh, J B Gibbs, 2001, Journal of medicinal chemistry.

Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agent.

M C Sanguinetti, J J Lynch, E P Baskin, 1993, The Journal of pharmacology and experimental therapeutics.